Fusco, Vittorio
Di Maio, Massimo
Valsecchi, Anna Amela
Santini, Daniele
Tucci, Marcello
De Giorgi, Ugo
Bossi, Paolo
Ibrahim, Toni
Cavanna, Luigi
Lanzetta, Gaetano
Rossi, Maura
Rossetti, Giorgia
Airoldi, Mario
Comandone, Alessandro
Cinieri, Saverio
Article History
Received: 8 May 2023
Accepted: 16 February 2024
First Online: 1 March 2024
Declarations
:
: This is a survey not involving patients, so ethics approval is not required.
: The web survey was compiled on a voluntary and anonymous basis, after e-mail invitation, in accordance with national and EU rules on the protection of the processing of personal and sensitive data (European Regulation n.679/2016, c.d. GDPR, and Italian legislation on Privacy). Therefore, no informed consent was signed because not required.
: MDM reports honoraria from AstraZeneca, Boehringer Ingelheim, Janssen, Merck Sharp & Dohme (MSD), Novartis, Pfizer, Roche, GlaxoSmithKline, Amgen, Merck, Takeda for consultancy or participation to advisory boards and direct research funding from Tesaro/GlaxoSmithKline, institutional funding for work in clinicaltrials/contracted research from Beigene, Exelixis, MSD, Pfizer and Roche. D.S. has served on advisory boards for Janssen, Astellas, MSD, Astra-Zeneca, Roche, Merck, Bayer, Novartis, Lilly, Amgen. M.R. has received travel grants by Novartis and Astra Zeneca. P.B. has received a research grant from Amgen. T.I. has received fee for advisory board from Amgen, Pharmamar and GlaxoSmithKline, and partecipation coverage at meeting from Pharmamar and Istituto Gentili. U.D.G. is consultant to Janssen, AstellasPharma, Sanofi, Bayer, Pfizer, Bristol-Myers Squibb, Novartis, Ipsen, Merck; has received institutional funding from Roche, Sanofi, AstraZeneca; and has received travel accommodation from Janssen-Cilag, IPSEN. S.C. is previous national AIOM president. Other authors (V.F; M.D.M; A.A.V.; G.R.; G.L.; L.C; M.A.; A.C.) declared to have no relevant financial or non-financial interests to disclose inherent to the paper.